By: Benzinga
January 30, 2013 at 09:01 AM EST
St. Jude Medical Announces First PAtient Enrollment in EnligHTN Renal Denervation Study
St. Jude Medical, Inc. (NYSE: STJ ), a global medical device company, today announced enrollment of the first patient in the EnligHTN II trial. This post-market clinical study will further evaluate the safety and efficacy of the EnligHTN^™ Renal Denervation System in patients with uncontrolled hypertension. According to the World Health Organization (WHO),
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here